Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Travere Therapeutics (TVTX - Free Report) will announce quarterly loss of $0.58 per share in its forthcoming report, representing an increase of 50% year over year. Revenues are projected to reach $73.44 million, increasing 63% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 9.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Travere metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus among analysts is that 'Revenue- Tiopronin products / Thiola' will reach $24.03 million. The estimate points to a change of -4.7% from the year-ago quarter.
Analysts forecast 'Revenue- FILSPARI' to reach $45.31 million. The estimate indicates a year-over-year change of +208.3%.
According to the collective judgment of analysts, 'Revenue- License and collaboration revenue' should come in at $4.77 million. The estimate points to a change of -7.2% from the year-ago quarter.
View all Key Company Metrics for Travere here>>>
Travere shares have witnessed a change of +24.7% in the past month, in contrast to the Zacks S&P 500 composite's +4.7% move. With a Zacks Rank #3 (Hold), TVTX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>